Table 1.

Demographic data of 1024 individuals who underwent 1116 percutaneous ultrasound-guided native kidney biopsies

ParameterComplication(n = 84; 7.5%)No Complication(n = 1032; 92.5%)PHIV Positive(n = 243; 21.8%)HIV Negative(n = 873; 78.2%)P
Age (yr; mean ± SD)46.0 ± 14.345.0 ± 15.00.645.0 ± 8.245.1 ± 16.40.8
Women (n [%])49 (58.3)579 (56.1)0.788 (36.2)540 (61.9)<0.001
Black (n [%])45 (53.6)593 (57.9)0.4217 (89.3)421 (48.6)<0.001
Hypertension (n [%])26 (31.0)285 (27.6)0.5137 (56.4)174 (19.9)<0.001
Diabetes (n [%])13 (15.5)111 (10.8)0.226 (10.7)98 (11.2)0.8
Hepatitis C (n [%])22 (28.6)152 (16.5)0.007132 (54.3)42 (5.6)<0.001
HIV positive (n [%])21 (25.0)222 (21.5)0.5NANANA
Prebiopsy hematocrit (%; mean ± SD)32.5 ± 5.733.5 ± 5.90.232.4 ± 6.033.6 ± 5.90.006
Pre-biopsy hematocrit <30% (n [%])29 (35.4)299 (29.8)0.387 (37.5)241 (28.2)0.006
Prebiopsy platelet count (1000 cells/mm3; mean ± SD213.1 ± 75.6251.6 ± 101.7<0.001207.5 ± 92.7259.9 ± 99.5<0.001
Prebiopsy platelet count <100,000 cells/mm3 (n [%])8 (9.5)41 (4.1)0.0517 (7.2)32 (3.7)0.02
Prebiopsy serum creatinine (mg/dl; median [IQR])1.8 (1.0 to 3.8)1.9 (1.0 to 3.8)0.72.7 (1.7 to 4.9)1.7 (0.9 to 3.4)<0.001
Prebiopsy BUN (mg/dl; median [IQR])28.5 (17.0 to 49.0)29.0 (18.0 to 47.0)0.934.0 (21.0 to 45.0)28.0 (17.0 to 47.0)0.01
Prebiopsy eGFR (ml/min per 1.73 m2; median [IQR])a43.6 (16.7 to 60.0)41.1 (18.0 to 60.0)0.729.2 (14.4 to 49.8)45.7 (18.9 to 60.0)<0.001
Prebiopsy eGFR <30 ml/min per 1.73 m2 (n [%])29 (34.9)426 (42.0)0.2126 (51.9)329 (38.5)<0.001
  • Columns may not sum to total due to missing data. IQR, interquartile range.

  • a eGFR >60 ml/min per 1.73 m2 expressed as 60.